Pharsight

Arcutis patents expiration

1. Zoryve patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884050 ARCUTIS Inhibition of crystal growth of roflumilast
Jun, 2037

(13 years from now)

US9907788 ARCUTIS Inhibition of crystal growth of roflumilast
Jun, 2037

(13 years from now)

US10940142 ARCUTIS Inhibition of crystal growth of roflumilast
Jun, 2037

(13 years from now)

US11129818 ARCUTIS Topical roflumilast formulation having improved delivery and plasma half life
Aug, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Jul 29, 2025

Drugs and Companies using ROFLUMILAST ingredient

Market Authorisation Date: 29 July, 2022

Treatment: Topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. (1)

Dosage: CREAM;TOPICAL

More Information on Dosage

ZORYVE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic